{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-26-027202","form_type":"8-K","ticker":"MIRA","cik":"0001904286","company_name":"MIRA PHARMACEUTICALS, INC.","filed_at":"2026-06-04T12:00:41+00:00","discovered_at":"2026-06-04T12:05:00.305210+00:00","generated_at":"2026-06-04T12:06:20.147446+00:00","sec_items":["1.01","7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"MIRA secures worldwide exclusive rights to MIRA-55 and SKNY-1 via amended license","bullets":["Amended license with MIRALOGX LLC grants MIRA global exclusive rights to develop, commercialize, sublicense, and enforce IP for MIRA-55 and SKNY-1.","Core economic terms from prior license arrangements remain materially unchanged; no upfront or milestone payments disclosed.","MIRA CEO says the company now controls worldwide rights across entire pipeline: Ketamir-2, MIRA-55, and SKNY-1.","MIRA-55 targets chronic inflammatory pain; SKNY-1 targets obesity and addiction-related disorders—both investigational.","Agreement consolidates IP portfolio and enhances flexibility for future licensing and partnership opportunities."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-027202","json":"https://secwatch.observer/filing/0001493152-26-027202.json","markdown":"https://secwatch.observer/filing/0001493152-26-027202.md","text":"https://secwatch.observer/filing/0001493152-26-027202.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1904286/000149315226027202/0001493152-26-027202-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1904286/000149315226027202/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T12:06:20.147446+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"b0a935d3e461b187629356af45019642aaf51db7","claim":"MIRA PHARMACEUTICALS, INC. amended Amended and Restated Exclusive License Agreement with MIRALOGX LLC (effective 2026-06-03).","evidence_excerpt":"On June 3, 2026, MIRA Pharmaceuticals, Inc. (the \"Company\") entered into an Amended and Restated Exclusive License Agreement (the \"License Agreement\") with MIRALOGX LLC (\"Miralogx\").","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1904286/000149315226027202/0001493152-26-027202-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"amendment"},{"label":"Agreement","value":"license"},{"label":"Counterparty","value":"MIRALOGX LLC"},{"label":"Effective","value":"2026-06-03"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}